Clinical Trials Logo

Clinical Trial Summary

The goal of this multicentre, prospective, open-label, cross-over clinical study is to determine whether individualized PK-guided dosing of emicizumab is non-inferior to conventional dosing of emicizumab in the prevention of bleeding in congenital haemophilia A patients.


Clinical Trial Description

Haemophilia A is an X-linked hereditary bleeding disorder resulting from a deficiency or dysfunction of endogenous coagulation factor VIII (FVIII). Persons with haemophilia A (PwHA) suffer from spontaneous or provoked bleeding, predominantly into major joints, which eventually lead to painful and chronic disabling arthropathy. The primary goal in clinical management of haemophilia A is prevention of bleeding by self-administration of FVIII concentrates via intravenous injections. Prophylaxis with FVIII concentrates has effectively reduced treated bleeds from an annual average of 20-30 to 1-4. However, in approximately 30% of PwHA anti-FVIII antibodies (known as inhibitors) develop that interfere with FVIII replacement therapy. PwHA who develop inhibitors require alternative suboptimal therapy with (costly) bypassing agents (BPA). The first approved non-factor therapy is the bispecific, FVIII-mimicking antibody, emicizumab (Hemlibra®), which came available in the Netherlands in July 2018. Emicizumab is a humanized, bispecific antibody connecting factor IX and factor X enabling the activation of FX and subsequent thrombin generation. Emicizumab has shown to be highly effective prophylaxis in PwHA by achieving a complete eradication of treated bleeds in around 80% of PwHA (n = 374) during the second 24-week interval of treatment. Furter advantages of emicizumab are the subcutaneous administration and less frequent dosing intervals every 1, 2 or 4 weeks due to a long half-life (t ½: 28 days). Despite many PwHA are candidate for prophylaxis with emicizumab, cost limit widespread access. Currently, emicizumab is approved by F. Hoffmann-La Roche® with a loading dose of 3 mg/kg/week for four weeks and a maintenance dose of 1.5 mg/kg/week, 3 mg/kg/2 weeks or 6 mg/kg/4 weeks. These dose regimens were based on a pharmacometric approach instead of a dose finding study, and targeted a trough concentration (Ctrough) of 45 µg/ml by using pharmacokinetic (PK)simulations. Meanwhile long-term bleed data from the phase III and IV studies by the pharmaceutical company were included in pharmacokinetic (PK) and pharmacodynamic (PD) modelling studies, and the effective Ctrough was suggested at 30 µg/ml. Although this Ctrough of 30 µg/ml is substantially lower than the previous Ctrough (45 µg/ml), the dose regimens were not adjusted. Conventional dosing leads to mean concentrations of 55 µg/ml with two thirds of the observations between 40 and 70 µg/ml (i.e., SD of ±15 µg/ml). Emicizumab has been approved based on fixed body-weight-based dosing and therefore the concentration target might have been kept higher to avoid lower effectivity due to inter-patient variability. However, reduced dosing of emicizumab, either by extending the dosing interval or lowering the dose, without sacrificing its efficacy has been reported in small case series. Therefore, the investigators hypothesized that lower dosing of emicizumab targeted at Ctrough 30 μg/mL, is equally as effective and less costly in preventing bleeds as conventional dosing of emicizumab, and designed the DosEmi study to investigate the hypothesis in a large prospective cohort of adult and paediatric PwHA. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT06320626
Study type Interventional
Source UMC Utrecht
Contact Kathelijn Fischer, Dr, MD.
Phone +318 875 584 50
Email k.fischer@umcutrecht.nl
Status Recruiting
Phase Phase 4
Start date September 8, 2022
Completion date August 2026

See also
  Status Clinical Trial Phase
Completed NCT04011852 - The Role of Chest Electrical Impedance Tomography in the Pediatric Ventilator Weaning
Completed NCT03497663 - VIA Family - Family Based Early Intervention Versus Treatment as Usual N/A
Recruiting NCT05016271 - Health Benefits of Air Purifiers in Primary School Students N/A
Completed NCT02551978 - Kids Obesity Prevention Program - Study (KOP) N/A
Completed NCT02240368 - Performance Evaluation of the Depth of Anesthesia Monitors in Pediatric Surgery
Completed NCT03946137 - Chest Therapy and Postural Education in Children With Cerebral Palsy N/A
Completed NCT01918020 - Impact Study of Minnesota SNAP-Ed Health and Nutrition Education Programs N/A
Completed NCT01267097 - The PAC Study: Parents as Agents of Change in Pediatric Weight Management N/A
Recruiting NCT04022460 - Using Personal Mobile Technology to Identify Obstructive Sleep Apnea in Children With Down Syndrome (UPLOAD)
Completed NCT05538039 - Reducing Anxiety of Children and Their Parents in the Pre-elective Surgery Process N/A
Completed NCT03156465 - Iowa Cochlear Implant Clinical Research Center Hybrid L24 and Standard Cochlear Implants in Profoundly Deaf Infants N/A
Not yet recruiting NCT05914324 - Outpatient Pediatric Pulse Oximeters in Africa N/A
Not yet recruiting NCT04827108 - Psychometric Properties of the Chinese Version of PeNAT
Recruiting NCT04888195 - Symptom Clusters in Hong Kong Chinese Children With Blood Cancer
Not yet recruiting NCT04853303 - VR to Improve CINV, Sleep and Pain Among Children With Cancer in HK N/A
Completed NCT05374902 - Efficacy of Animation, Buzzy, and Multiple Interventions on Pain in Children N/A
Completed NCT04665453 - Dexmedetomidine and Melatonin for Sleep Induction for EEG in Children N/A
Completed NCT04082247 - Healthy Children 2021 Study in Childcare Centers N/A
Completed NCT02858531 - Predictive Tracking of Patient Flow in the Emergency Services During the Virus Winter Epidemics
Terminated NCT04009031 - Video Game for Home-based Rehabilitation for Children With Hemiplegia N/A